logo
Plus   Neg
Share
Email

4D Collaborates With Merck To Develop Live Biotherapeutics For Vaccines

4D pharma plc (DDDD.L) said it reached a research collaboration and option to license agreement with Merck & Co., Inc. (MRK) to discover and develop Live Biotherapeutics for vaccines.

As per the terms of the deal, 4D's proprietary MicroRx platform will be paired with Merck's expertise in the development and commercialisation of novel vaccines, to discover and develop Live Biotherapeutics as vaccines in up to three undisclosed indications.

4D has the right to cause Merck to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration.

In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration.

Merck will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Uber Technologies Inc. (UBER) said Monday that it laid off about 350 employees across several different teams, as part of its final phase of layoffs of the process it began earlier this year. Porsche unveiled a cheaper version of its Taycan all-electric sports car, Taycan 4S. This is the third version of the sports saloon after Taycan Turbo S and Taycan Turbo launched in September. According to Porsche, Taycan 4S is now the new entry-level model in the Taycan series. The new model is available is two versions based on battery sizes. Howard University and Amazon Studios have jointly launched Howard Entertainment. The program is meant to give African-American students and other marginalized populations such as Latinx and Native American students an opportunity to train and study alongside executives in the entertainment industry. The program will begin in January 2020.
Follow RTT
>